Inhibrx Biosciences Publishes HexAgon-HN Phase 2 Results Presentation

• Inhibrx Biosciences published its HexAgon-HN phase 2 primary analysis presentation on ordastobart with pembrolizumab for recurrent or metastatic head-and-neck cancer.
• The combination achieved a 48.3% confirmed response rate versus 26.5% with pembrolizumab alone; six-month progression-free survival was 72.4% versus 42.8%.
• Among HPV-positive patients, confirmed response rates reached 80% versus 33.3%; six-month progression-free survival was 90% versus 33%.
• Treatment-related grade 3 or higher adverse events occurred in 48.4% versus 11.8%; treatment discontinuations were 35.5% versus 14.7%.
• A 50-patient phase 2b expansion in HPV-positive oropharyngeal cancer with PD-L1 CPS ≥1 aims to support accelerated regulatory pathway discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.